BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  •
  • MyStocks
MEMBER'S LOGIN

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9%
Fri, 9 Nov

BIOCON LTD has announced its results for the quarter ended September 2018. Here is a detailed performance review of the same:

BIOCON LTD Quarterly Financials

No. of Mths
Qtr. Ending		3
Sep-17* 		3
Jun-18* 		3
Sep-18* 		QoQ ChangeYoY Change
Net SalesRs m9,68611,23813,21017.5%36.4%
Other incomeRs m508688544-20.9%7.1%
TurnoverRs m10,19411,92613,75415.3%34.9%
ExpensesRs m7,8638,8609,81410.8%24.8%
Gross profitRs m1,6202,3785,284122.2%226.2%
DepreciationRs m9369911,12213.2%19.9%
InterestRs m1381761886.8%36.2%
Profit before taxRs m1,0541,8994,518137.9%328.7%
TaxRs m42552173240.5%72.2%
Profit after taxRs m6291,3783,786174.7%501.9%
Gross profit margin%16.721.240.0
Effective tax rate%40.327.416.2
Net profit margin%6.211.627.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 36.4% on a year-on-year (YoY) basis. The expenses were up by 24.8% YoY during the same period.
  • The company's operating profit increased by 226.2% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 40.0% in 2QFY19 as against 16.7% in 2QFY18.
  • Depreciation charges increased by 19.9% and finance costs increased by 36.2% YoY, respectively.
  • Other income increased by 7.1% YoY during the quarter.
  • Net profit for the quarter increased by 501.9% YoY. Net profit margins during the quarter increased from 6.2% in 2QFY18 to 27.5% in 2QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 17.5% on a quarter-on-quarter (QoQ) basis. The expenses were up by 10.8% QoQ during the same period.
  • The company's operating profit increased by 122.2% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 40.0% in 2QFY19 as against 21.2% in 1QFY18.
  • Net profit for the quarter increased by 174.7% QoQ, while net profit margins increased from 11.6% in 1QFY18 to 27.5% in 2QFY19.

To see how BIOCON LTD has performed over the last eight quarters, please visit here.

BIOCON LTD Share Price Performance

Over the last one year, BIOCON LTD share price has moved up from Rs 400.7 to Rs 636.5, registering a Gain of Rs 235.9 or around 58.9%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,681.6 (up 1.0%). Over the last one year it has moved up from 13,987.8 to 14,681.6, a gain of 694 points (up 5.0%).

Overall, the S&P BSE SENSEX is up 5.3% over the year.

Current Valuations

At the current price of Rs 636.5, the price to earnings (P/E) ratio of BIOCON LTD stands at 50.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 7.4 times.

Equitymaster requests your view! Post a comment on "BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9%". Click here!

  

Related Views on News

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Dec 6, 2019 (Close)

TRACK BIOCON

MORE ON BIOCON

BIOCON 8-QTR ANALYSIS

Detailed Quarterly Results With Charts

COMPARE BIOCON WITH

OTHER USEFUL LINKS

MARKET STATS


ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
  • Get Equitymaster Android App on Google Play
  • Get Equitymaster iOS App on App Store
FOLLOW

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.